Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Melinta reports Phase III success for antibiotic

This article was originally published in Scrip

Executive Summary

Connecticut-based Melinta Therapeutics says that a Phase III study of its lead product, the investigational fluoroquinalone antibiotic, delafloxacin IV has met its primary end point.

You may also be interested in...



Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola

The latest drug development news and highlights from our FDA Performance Tracker.

EMA Scientific Advice Demand Up But Not For Orphan Drugs

The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.

NHS England And Vertex Strike “Lightening Quick” CF Kaftrio/Trikafta Deal

An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132940

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel